iPS cells reprogrammed from primary dendritic cells provide an abundant source of immunostimulatory dendritic cells for use in immunotherapy
Cell types differentiated from induced pluripotent stem cells (iPSCs) are frequently arrested in their development program, more closely resembling a fetal rather than an adult phenotype, potentially limiting their utility for downstream clinical applications. The fetal phenotype of iPSC‐derived den...
Principais autores: | Horton, C, Davies, TJ, Lahiri, P, Sachamitr, P, Fairchild, PJ |
---|---|
Formato: | Journal article |
Idioma: | English |
Publicado em: |
Wiley
2019
|
Registros relacionados
-
Cross presentation of antigen by dendritic cells: mechanisms and implications for immunotherapy.
por: Sachamitr, P, et al.
Publicado em: (2012) -
Towards the rational design of a next-generation dendritic cell vaccine for cancer immunotherapy
por: Bravo, M, et al.
Publicado em: (2021) -
Directed differentiation of human induced pluripotent stem cells into dendritic cells displaying tolerogenic properties and resembling the CD141+ subset
por: Sachamitr, P, et al.
Publicado em: (2018) -
Enhancement of tolerogenic or immunostimulatory potential of dendritic cells for therapeutic goals
por: Hanif, Javanmard Khameneh
Publicado em: (2011) -
Enhancement of tolerogenic or immunostimulatory potential of dendritic cells for therapeutic goals.
por: Hanif Javanmard Khameneh
Publicado em: (2014)